Stryker Co. (NYSE:SYK) is Blue Zone Wealth Advisors LLC’s 7th Largest Position

Blue Zone Wealth Advisors LLC reduced its stake in shares of Stryker Co. (NYSE:SYK) by 4.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,727 shares of the medical technology company’s stock after selling 1,006 shares during the period. Stryker accounts for about 2.6% of Blue Zone Wealth Advisors LLC’s holdings, making the stock its 7th biggest position. Blue Zone Wealth Advisors LLC’s holdings in Stryker were worth $7,418,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Carnegie Capital Asset Management LLC boosted its holdings in Stryker by 0.5% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock valued at $28,820,000 after acquiring an additional 497 shares during the last quarter. Atlantic Edge Private Wealth Management LLC bought a new position in shares of Stryker in the 4th quarter worth about $1,561,000. CoreCap Advisors LLC grew its position in shares of Stryker by 3.9% during the 4th quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock valued at $1,506,000 after buying an additional 191 shares during the last quarter. Consolidated Planning Corp acquired a new stake in Stryker during the fourth quarter worth about $205,000. Finally, Meritage Portfolio Management bought a new position in Stryker in the fourth quarter worth about $569,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.1 %

Shares of NYSE:SYK traded up $0.51 during mid-day trading on Friday, hitting $340.25. The stock had a trading volume of 1,894,420 shares, compared to its average volume of 1,082,587. The company’s 50 day moving average is $337.38 and its 200-day moving average is $333.91. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The company has a market cap of $129.62 billion, a PE ratio of 38.84, a P/E/G ratio of 2.68 and a beta of 0.92.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. The firm had revenue of $5.24 billion during the quarter, compared to analyst estimates of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the company posted $2.14 EPS. On average, sell-side analysts predict that Stryker Co. will post 11.95 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.94%. The ex-dividend date is Friday, June 28th. Stryker’s dividend payout ratio is currently 36.53%.

Analyst Ratings Changes

SYK has been the subject of a number of analyst reports. Piper Sandler boosted their price objective on Stryker from $375.00 to $380.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Royal Bank of Canada boosted their target price on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. TD Cowen boosted their price objective on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. BTIG Research raised their target price on Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, Citigroup increased their price target on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $370.58.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.